TY - JOUR A1 - Falkenbach, Fabian A1 - Ambrosini, Francesca A1 - Tennstedt, Pierre A1 - Eiber, Matthias A1 - Heck, Matthias M. A1 - Preisser, Felix A1 - Graefen, Markus A1 - Budäus, Lars A1 - Koehler, Daniel A1 - Knipper, Sophie A1 - Maurer, Tobias T1 - EAU biochemical recurrence risk classification and PSA kinetics have no value for patient selection in PSMA-radioguided surgery (PSMA-RGS) for oligorecurrent prostate cancer T2 - Cancers N2 - Objective: To assess the influence of biochemical recurrence (BCR) risk groups and PSA kinetics on the outcomes of radioguided surgery against prostate-specific membrane antigen (PSMA-RGS). Currently, neither BCR risk group nor PSA doubling time (PSA-DT), or PSA velocity (PSA-V) are actively assigned or relevant for counseling prior to PSMA-RGS. Methods: We retrospectively analyzed PSMA-RGS cases for oligorecurrent prostate cancer between 2014 and 2023. BCR risk groups, PSA-DT, and PSA-V were analyzed as predictors for complete biochemical response (cBR, PSA < 0.2 ng/mL), BCR-free, and therapy-free survival (BCRFS, TFS). Results: Of 374 included patients, only 21/374 (6%) and 201/374 (54%) were classified as low- and high-risk BCR (no group assignment possible in 152/374, 41%). A total of 13/21 (62%) patients with low- and 120/201 (60%) with high-risk BCR achieved cBR (p = 1.0). BCR classification was no predictor for BCRFS (HR:1.61, CI: 0.70-3.71, p = 0.3) or subsequent TFS (HR:1.07, CI: 0.46-2.47, p = 0.9). A total of 47/76 (62%) patients with PSA-DT ≤ 6 mo and 50/84 (60%) with PSA-DT > 6 mo achieved cBR (p = 0.4). PSA-DT was not associated with cBR (OR: 0.99, CI: 0.95-1.03, p = 0.5), BCRFS (HR: 1.00, CI: 0.97-1.03, p = 0.9), or TFS (HR: 1.02, CI: 0.99-1.04, p = 0.2). Consistent negative findings were recorded for PSA-V. Conclusions: The BCR risk groups and PSA kinetics do not predict the oncological success of PSMA-RGS performed at low absolute PSA values. Indolent low-risk BCR is rarely treated by PSMA-RGS. Y1 - 2023 UR - https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/124391 UR - https://nbn-resolving.org/urn:nbn:de:bvb:384-opus4-1243916 SN - 2072-6694 VL - 15 IS - 20 SP - 5008 PB - MDPI AG ER -